Here, we focused on the concurrent contribution of three main tumor suppressor genes, namely TP53, BECN1 and BRCA1, in determining the clinical response to therapy and clinical outcome in ovarian cancer patients. This evidence concerns the gene BRCA1 and neoplasm.